Titus Abraham, MD
Internal Medicine · Annapolis, MDNPI 1598764540
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,260 of the $6,148 with a category attached, or 85.6%. 43 manufacturers reported payments, led by Modernatx, Inc. at 25.1% of the total. Reporting peaked in 2024 at $2,912 and has fallen 51.7% since, to $1,407 in 2025. Among internal medicine clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 248 payments — averaging $24.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$2K
- AbbVie$791
- Pfizer$675
- Novo Nordisk$574
- Astellas Pharma US Inc$288
- GSK$247
- plus $2K from 37 others
Across 136 payments — averaging $12,621 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$596K
- Exact Sciences$324K
- AstraZeneca$318K
- Genentech, Inc.$246K
- Merck$151K
- Amgen$59K
- plus $22K from 1 others
What the payments were for
- Travel & lodging$88814%
- Food & beverage$5,26086%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 17 | $1,541 |
| AbbVie | 38 | $791 |
| Pfizer | 35 | $675 |
| Novo Nordisk | 29 | $574 |
| Astellas Pharma US Inc | 14 | $288 |
| GSK | 13 | $247 |
| Lilly USA, LLC | 12 | $245 |
| Amgen | 11 | $206 |
| Exact Sciences | 6 | $156 |
| Merck | 5 | $128 |
| Boehringer Ingelheim | 6 | $110 |
| Sumitomo Pharma America, Inc. | 5 | $94 |
| AstraZeneca | 5 | $84 |
| Abbott | 5 | $82 |
| Medtronic(3 entities) | 3 | $69 |
| Johnson & Johnson | 3 | $64 |
| Insulet Corporation | 3 | $64 |
| Seqirus USA Inc | 4 | $62 |
| Hologic Sales And Service, LLC | 2 | $46 |
| Lundbeck LLC | 2 | $45 |
| Novartis | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Idorsia Pharmaceuticals US Inc | 2 | $41 |
| BD | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $34 |
| Abiomed | 1 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $28 |
| Tactile Systems Technology Inc | 1 | $24 |
| Array Biopharma Inc | 1 | $23 |
| Vertical Pharmaceuticals, LLC | 1 | $22 |
| Cequr Corporation | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Lifescan, Inc. | 1 | $21 |
| Gilead | 1 | $21 |
| Bayer | 1 | $20 |
| TMS Neurohealth Centers Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Baxter Healthcare | 1 | $16 |
| Biotronik Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$6,148 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 83 | $103,162 |
| JardianceEmpagliflozin | 42 | $67,482 |
| OzempicSemaglutide | 39 | $50,979 |
| XareltoRivaroxaban | 45 | $36,678 |
| RybelsusSemaglutide | 12 | $30,855 |
| MounjaroTirzepatide | 28 | $30,482 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $22,923 |
| FarxigaDapagliflozin Propanediol | 13 | $17,105 |
| TrulicityDulaglutide | 16 | $15,135 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $14,489 |
| Rosuvastatin Calcium | 398 | $11,594 |
| Atorvastatin Calcium | 725 | $11,211 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $11,066 |
| Pravastatin Sodium | 215 | $4,511 |
| Levothyroxine Sodium | 344 | $4,442 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $675 | $103,16283 claims |
| Novo NordiskOzempic, Rybelsus | $574 | $81,83451 claims |
| Boehringer IngelheimJardiance | $110 | $67,48242 claims |
| Lilly USA, LLCMounjaro, Trulicity | $245 | $45,61644 claims |
| GSKAnoro Ellipta, Trelegy Ellipta | $247 | $37,41228 claims |
| Johnson & JohnsonXarelto | $64 | $36,67845 claims |
| AstraZenecaFarxiga | $84 | $17,10513 claims |
| AbbVieSynthroid | $791 | $2,23039 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Annapolis
- Brian HarveyAnnapolis$220K
- Aditya ChopraAnnapolis$85K
- Marianne MannHighland$2.1M
- Param DedhiaBaltimore$636K
- Curtis RosebraughAshton$418K
- Mark CorriereColumbia$402K
- Gregory PokrywkaTowson$377K
- Shawn DhillonBaltimore$227K
- Jeremy SugarmanBaltimore$210K
- Florence HounPotomac$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.